Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1643 1645 1653 1671
This examiner grants 67% of resolved cases
Alec Jon Peters operates in Art Unit 1641 within Tech Center 1600. The examiner has 42 resolved cases. The allowance rate for these cases is 66.7 percent. This suggests a favorable environment for reaching allowance. The examiner's record provides an initial look at prosecution history in this unit.
The interview lift is 54.5 percent, suggesting that interviews are highly effective for increasing the chances of success compared to the baseline rate of 66.7 percent. Practitioners should consider this tactic to resolve outstanding issues. The median time to allowance is 1358 days. This pendency helps applicants estimate the time required to reach a final decision.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18553391 | GUCY2C BINDING POLYPEPTIDE AND USES THEREOF | Non-Final OA | LG CHEM, LTD. |
| 17762694 | KNOTTIN-IMMUNOSTIMULANT CONJUGATES AND RELATED COMPOSITIONS AND METHODS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18252285 | NPC1 MONOBODIES AND MONOBODY CONJUGATES THEREOF | Non-Final OA | NEW YORK UNIVERSITY |
| 18324668 | ANTI-BCMA ANTIBODIES | Final Rejection | SANOFI |
| 17817925 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | Final Rejection | Hoffmann-La Roche Inc. |
| 18552086 | CAR-T DELIVERY OF SYNTHETIC PEPTIDE THERAPEUTICS | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18038886 | MOLECULES WITH MULTIPLE BINDING DOMAINS | Non-Final OA | AMGEN RESEARCH (MUNICH) GMBH |
| 17786186 | MULTI-SPECIFIC T CELL RECEPTORS | Final Rejection | OREGON HEALTH & SCIENCE UNIVERSITY |
| 18263129 | FIBROBLAST ACTIVATION PROTEIN MODULATION TO ALTER IMMUNE CELL MIGRATION AND TUMOR INFILTRATION | Non-Final OA | Georgetown University |
| 18569115 | ANTI-IL-36R ANTIBODY AND USE THEREOF | Non-Final OA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 18572300 | COMBINATION THERAPY USING ANTIBODY-DRUG CONJUGATES | Non-Final OA | MEDIMMUNE LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy